CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
(PK) similarity and efficacy, safety, and immunogenicity of ABP 206 compared with OPDIVO® (nivolumab) in subjects with resected advanced melanoma...
Phase 3
Baltimore, Maryland, United States and 105 other locations
alone in participants with untreated, unresectable or metastatic melanoma. Participants randomized to the pembrolizumab monotherapy arm who ...
Phase 3
Bethesda, Maryland, United States and 32 other locations
of ANV419 with anti-PD1 antibody or with anti-CTLA4 antibody in adult participants with advanced (unresectable or metastatic) cutaneous melanoma...
Phase 1, Phase 2
Fairfax, Virginia, United States and 24 other locations
assess the efficacy, safety, and immunogenicity of ABP 206 compared with Nivolumab in Subjects with Treatment-Naïve Unresectable or Metastatic Melanoma...
Phase 3
Baltimore, Maryland, United States and 84 other locations
of ceralasertib, when administered as monotherapy and in combination with durvalumab in participants with unresectable or advanced melanoma ...
Phase 2
Lutherville-Timonium, Maryland, United States and 63 other locations
patients with unresectable Stage III or IV melanoma. The contributions of BNT111 and cemiplimab will be delineated in single agent...
Phase 2
Fairfax, Virginia, United States and 52 other locations
treatment of adult subjects with completely treated high-risk ocular melanoma, as defined in eligibility criteria, without evidence of metas...
Phase 2
Washington, District of Columbia, United States and 5 other locations
Part 1 is the dose escalation of APG-115 in combination with label dose of pembrolizumab.Part 2 is phase II design of APG-115 at recommended phase 2...
Phase 1, Phase 2
Washington, District of Columbia, United States and 19 other locations
to assess nivolumab plus relatlimab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma...
Phase 3
Washington, District of Columbia, United States and 171 other locations
(Spartalizumab (PDR001)), a BRAF inhibitor (dabrafenib) and a MEK inhibitor (trametinib) in unresectable or metastatic BRAF V600 mutant melanoma...
Phase 3
Lutherville, Maryland, United States and 178 other locations
Clinical trials
Research sites
Resources
Legal